Cardioprotective Efficacy Of Eclipta Alba Methanolic Extract In Doxorubicin Induced Oxidative Cardiac Damage

Q: What are the key findings of this study?

Methanolic extract of Eclipta Alba (200 and 400 mg/kg) returned abnormal biochemical levels to normal in rats with doxorubicin-induced heart injury, demonstrating cardioprotective efficacy.

Q: What is the clinical evidence from this study?

Population: Doxorubicin-induced cardiotoxicity. Intervention: Methanolic extract of Eclipta Alba (MEEA) vs. Vehicle, DOX alone, or conventional Digoxin. Primary outcome: Blood cardiac indicators, lipid peroxidation, protein carbonyl content, and antioxidant levels (p=p<0.05).

Q: What does this research mean for the field?

Methanolic extract of Eclipta alba attenuates doxorubicin-induced cardiotoxicity and oxidative stress in rats by normalizing cardiac biomarker levels and restoring endogenous antioxidant defenses. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To assess the cardioprotective efficacy of methanolic extract of Eclipta alba against doxorubicin-induced oxidative cardiac damage.

Aithamraju Satish Chandra, V. Alagarsamy, V. Radhika ,P. Subhash Chandra Bose, V. Ravi Kumar

doi:10.47750/pnr.2023.14.03.335

February 22, 2023Journal of Pharmaceutical Negative Results

Cardioprotective Efficacy Of Eclipta Alba Methanolic Extract In Doxorubicin Induced Oxidative Cardiac Damage

View Full Paper

Ask AI

Bookmark

Share

Key result

Eclipta alba extract normalizes cardiac biomarkers and reduces oxidative stress in doxorubicin-induced cardiotoxicity.

P<0.05

Why the study?

The preclinical effectiveness of methanolic extract of Eclipta Alba in doxorubicin-induced cardiotoxicity was not established.

Does methanolic extract of Eclipta Alba prevent doxorubicin-induced oxidative cardiac damage in a rat model?

Key Points

To assess the cardioprotective efficacy of methanolic extract of Eclipta alba against doxorubicin-induced oxidative cardiac damage.
Randomized animals across five groups receiving vehicle, doxorubicin (15 mg/kg, i.p.), MEEA (200 and 400 mg/kg, p.o.), or conventional digoxin for 14 days.
Administered doxorubicin on treatment days 13 and 14 to induce acute myocardial damage.
Measured serum cardiac injury markers (creatine kinase, lactate dehydrogenase, cardiac troponin I), tissue antioxidants (SOD, CAT, GPx, GSH), lipid peroxidation, and protein carbonyl levels.
Doxorubicin treatment caused significant increases (p < 0.05) in serum cardiac biomarkers, lipid peroxidation, and protein carbonyl content.
Endogenous antioxidant levels (SOD, CAT, GPx, and GSH) in cardiac tissue were significantly reduced by doxorubicin exposure.
Oral administration of MEEA at 200 and 400 mg/kg restored altered cardiac enzyme and oxidative stress markers back to baseline levels.

Structured PICO

Does methanolic extract of Eclipta Alba prevent doxorubicin-induced oxidative cardiac damage in a rat model?

P

Population

Rats with doxorubicin-induced cardiotoxicity treated for 14 days.

I

Intervention

Methanolic extract of Eclipta Alba (MEEA) 200 and 400 mg/kg orally for 14 days

C

Comparator

Vehicle control, DOX alone (15 mg/kg i.p.), and conventional Digoxin

O

Outcome

Blood cardiac indicators (creatine kinase, lactate dehydrogenase, cardiac troponin I), lipid peroxidation, protein carbonyl content, and antioxidant levels (SOD, CAT, Gpx, GSH) in heart tissuesurrogate

Main Result

p-value: p<0.05

Methanolic extract of Eclipta Alba shows potential cardioprotective efficacy against doxorubicin-induced oxidative cardiac damage in a preclinical rat model.

Implication

Does not support clinical use; leaves open whether Eclipta alba prevents doxorubicin cardiotoxicity in humans.

Abstract

The goal of the current investigation was to assess the preclinical effectiveness of doxorubicin (DOX)induced cardiotoxicity and methanolic extract of Eclipta Alba (MEEA). Except for the control group, animals were separated into five groups at random and given either a vehicle (15 mg/kg, i.p.) or DOX (15 mg/kg, i.p.) or MEEA (200 and 400 mg/kg, p.o.) or conventional Digoxin for 14 days. On the 13th and 14th days of treatment, DOX was administered. DOXimpaired rats had a substantial (p0.05) rise in blood cardiac indicators (creatine kinase, lactate dehydrogenase, and cardiac troponinI), lipid peroxidation, and protein carbonyl content, as well as a decrease in the levels of antioxidants (SOD, CAT, Gpx, and GSH) in the heart tissue. MEEA (200 and 400mg/kg, p.o.) treatment returned the abnormal biochemical level to normal. As a result, the study's findings indicate that MEEA demonstratedPotential cardioprotective efficacy in DOXinduced heart injury, mediated by its membrane stabilising and antioxidant impact

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aithamraju Satish Chandra, V. Alagarsamy, V. Radhika ,P. Subhash Chandra Bose, V. Ravi Kumar (2023) studied Doxorubicin-induced cardiotoxicity. Methanolic extract of Eclipta Alba (MEEA) vs. Vehicle, DOX alone, or conventional Digoxin was evaluated on Blood cardiac indicators, lipid peroxidation, protein carbonyl content, and antioxidant levels (p=p<0.05). Methanolic extract of Eclipta Alba (200 and 400 mg/kg) returned abnormal biochemical levels to normal in rats with doxorubicin-induced heart injury, demonstrating cardioprotective efficacy.

synapsesocial.com/papers/6ac2eef270c065e257f28db7 https://doi.org/10.47750/pnr.2023.14.03.335

View Full Paper

Ask AI

Bookmark

Share

Cardioprotective Efficacy Of Eclipta Alba Methanolic Extract In Doxorubicin Induced Oxidative Cardiac Damage

Key Points

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Cardioprotective Efficacy Of Eclipta Alba Methanolic Extract In Doxorubicin Induced Oxidative Cardiac Damage

Key Points

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading